Cadrenal Therapeutics Q4 2023 Earnings Report $12.96 +1.51 (+13.19%) (As of 12/18/2024 05:45 PM ET) Earnings HistoryForecast Cadrenal Therapeutics EPS ResultsActual EPS-$0.05Consensus EPS -$0.09Beat/MissBeat by +$0.04One Year Ago EPSN/ACadrenal Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACadrenal Therapeutics Announcement DetailsQuarterQ4 2023Date3/11/2024TimeN/AConference Call ResourcesPress ReleaseCVKD Earnings History This Crypto Is Set to Explode in December (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Cadrenal Therapeutics Earnings HeadlinesCadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner MeetingsDecember 18 at 6:00 PM | finance.yahoo.comCVKD: Recent Financings Raise $9.8 Million…November 20, 2024 | msn.comThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…December 19, 2024 | Crypto 101 Media (Ad)Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech OutlookNovember 19, 2024 | prnewswire.comCadrenal Therapeutics files to sell 590K shares of common stock for holdersNovember 15, 2024 | markets.businessinsider.comCADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESSNovember 12, 2024 | prnewswire.comSee More Cadrenal Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cadrenal Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cadrenal Therapeutics and other key companies, straight to your email. Email Address About Cadrenal TherapeuticsCadrenal Therapeutics (NASDAQ:CVKD) operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.View Cadrenal Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
